AOD-9604 monograph

AOD-9604 Monograph

^[1]

This page preserves the structured raw monograph for TroponinIQ Base under the shared content policy. The content is factual reference material; it is not a production prompt or constant update. No Production target: directive was present in the source.

Curation Summary

• Class: Synthetic peptide; C-terminal fragment analog of human growth hormone (hGH) 177-191
• Legal/regulatory status: Not FDA-approved for obesity or bodybuilding use. No FDA-approved product containing AOD-9604 was identified in the sources reviewed. WADA treats it as a banned performance-enhancing peptide according to the anti-doping literature; the WADA Prohibited List page reviewed here did not explicitly name AOD-9604 in the accessible page text, so the safest statement is that it is covered by anti-doping prohibition and has been described in PubMed as banned by WADA. It is effectively a research-chemical / gray-market compound in non-medical contexts.
• Routing: module 03 knowledge for mechanism, clinical/performance context, legal status, safety, and FAQ retrieval.
• Source hash: 64ad385fb293d07c42840c6a0014eb72ff96c9a7733891fa3573b64a9b897e14

Overview Extract

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, designed to mimic GH’s lipolytic activity without the classic diabetogenic effects. The human evidence base is thin: there were phase IIa obesity trials underway in the early 2000s, but widely accessible public summaries do not provide robust clinical efficacy or pharmacokinetic detail. In sports contexts, it is treated as a prohibited performance-enhancing peptide and is not an approved obesity drug.

Use-Case Anchors

• Primary goals: Experimental obesity/fat-loss agent; intended for reduction of body fat and potentially increased lipolysis/fat oxidation. In bodybuilding communities it is often framed as a cutting/fat-loss peptide, but clinical benefit remains unproven.

Safety / Legal Anchors

• Common side effects: Human safety data are limited; commonly discussed adverse effects are injection-site irritation and nonspecific peptide-related complaints such as headache, flushing, or GI upset, but these are not well quantified in controlled human trials. Because robust clinical safety data are sparse, even "common" side effects should be interpreted cautiously.

FAQ Anchors

• Q: Does AOD-9604 actually burn fat?

Source Text

AOD-9604

Overview

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, designed to mimic GH’s lipolytic activity without the classic diabetogenic effects. The human evidence base is thin: there were phase IIa obesity trials underway in the early 2000s, but widely accessible public summaries do not provide robust clinical efficacy or pharmacokinetic detail. In sports contexts, it is treated as a prohibited performance-enhancing peptide and is not an approved obesity drug.

Pharmacokinetics & Mechanism

• Class: Synthetic peptide; C-terminal fragment analog of human growth hormone (hGH) 177-191
• Mechanism of action: Proposed to promote lipolysis and fat oxidation and to increase lipolytic sensitivity, with preclinical data implicating beta-adrenergic signaling and beta-3 adrenergic receptor expression. In obese mice, chronic AOD-9604 increased beta-3-AR RNA expression and reduced body weight/body fat, but the study concluded the lipolytic effect was not directly mediated by beta-3-AR. Human receptor-level pharmacology and definitive mechanism in humans are not well established.
• Target(s): Best-supported preclinical target/pathway: beta-adrenergic pathway, especially beta-3 adrenergic receptor expression/signaling. No validated human receptor target or downstream pathway is definitively established.
• Route(s) of administration: Injectable peptide in research/bodybuilding use; the preclinical study used intraperitoneal administration in mice. Human trial route is not clearly established in the accessible public record here, and community use is typically reported as subcutaneous injection. Oral bioavailability is not established and is not used clinically.
• Onset: Not well established in humans. In animal work, metabolic effects were assessed after chronic treatment over 14 days, with an acute increase in energy expenditure/fat oxidation also observed in beta-3-AR knock-out mice.
• Half-life: Not well established in humans. Publicly accessible sources located here do not provide a validated human half-life. A separate anti-doping/metabolism paper focused on detection found six metabolites and a more stable serum metabolite, but did not establish a clinical half-life. If a chatbot needs to mention kinetics, use "not well established" rather than guessing.
• Metabolism / clearance: In vitro work showed AOD9604 is metabolized in serum and urine into multiple metabolites; one serum metabolite (CRSVEGSCG) was more stable than parent compound and other metabolites. Human systemic clearance pathways are not well established from the accessible sources; anti-doping work suggests peptide metabolism is rapid enough that metabolite-based detection may extend the detection window.

Use-Cases & Dosing Strategies

• Primary goals: Experimental obesity/fat-loss agent; intended for reduction of body fat and potentially increased lipolysis/fat oxidation. In bodybuilding communities it is often framed as a cutting/fat-loss peptide, but clinical benefit remains unproven.
• Typical protocols: Clinical: public PubMed-accessible sources here only confirm phase IIa trials were underway; they do not provide a validated clinical dose or schedule, so the clinical protocol is not well established from the sources retrieved. Community/anecdotal: commonly discussed as a subcutaneous peptide used in repeated daily or near-daily injections for cutting, but exact doses vary widely across vendors/forums and are not reliable enough to present as fact. Because accurate human dosing is not established in the accessible literature, do not present a standard dose as clinical guidance.
• Cycle length: Not well established clinically. Community use is typically described as several weeks to a few months, but that is anecdotal and highly variable; no evidence-based cycling standard was identified in authoritative sources.
• Common stacks: Anecdotally stacked with other bodybuilding fat-loss or recovery agents such as CJC-1295/Ipamorelin, GH secretagogues, or a calorie-deficit cutting phase. These combinations are community practice, not evidence-based clinical guidance.
• Reconstitution / handling (peptides): As a peptide, it is typically handled by reconstitution with bacteriostatic water in community use, then refrigerated after reconstitution; avoid heat, shaking, and repeated contamination. Exact handling instructions from an approved manufacturer monograph were not located, so this should be treated as general peptide-handling practice rather than product-specific medical guidance.
• Notes: Bioavailability and timing are not well established in humans. Community users often time injections around fasting or pre-cardio windows to target fat loss, but there is no authoritative evidence that timing meaningfully changes outcomes. Do not infer a validated dose-response relationship from bodybuilding anecdotes.

Clinical vs. community/anecdotal labeling is noted inline above. Community dosing is not established fact.

Side Effects & Safety / Legal

• Common side effects: Human safety data are limited; commonly discussed adverse effects are injection-site irritation and nonspecific peptide-related complaints such as headache, flushing, or GI upset, but these are not well quantified in controlled human trials. Because robust clinical safety data are sparse, even "common" side effects should be interpreted cautiously.
• Serious / less common: Serious human adverse effects are not well established in the accessible literature. The major practical concerns are product quality/sterility, unknown long-term endocrine/metabolic effects, and the possibility of using a prohibited substance in sport. Any unexpected edema, allergic reaction, persistent hyperglycemia, or systemic reaction should be treated as potentially serious, but frequency data are lacking.
• Contraindications: No authoritative contraindication list was identified. Reasonable caution is warranted in pregnancy, diabetes or impaired glucose regulation, active cancer, significant cardiovascular disease, and any situation where immunogenicity, infection risk, or anti-doping testing matters. Potential interactions with other lipolytic agents, GH-axis drugs, or stimulants are unstudied.
• Monitoring: If used outside a research setting, monitor body weight, waist, blood pressure, fasting glucose, HbA1c, lipids, and any injection-site or hypersensitivity reactions. Because human safety data are thin, periodic CMP/CBC and symptom review are reasonable, but no validated biomarker-monitoring protocol exists for AOD-9604 specifically.
• Legal / regulatory status: Not FDA-approved for obesity or bodybuilding use. No FDA-approved product containing AOD-9604 was identified in the sources reviewed. WADA treats it as a banned performance-enhancing peptide according to the anti-doping literature; the WADA Prohibited List page reviewed here did not explicitly name AOD-9604 in the accessible page text, so the safest statement is that it is covered by anti-doping prohibition and has been described in PubMed as banned by WADA. It is effectively a research-chemical / gray-market compound in non-medical contexts.

Coach Voice Notes

AOD-9604 is mostly a fat-loss story, not a muscle-building one. The human evidence is weak enough that I would not sell it as a reliable cutter, especially when the dose, half-life, and real-world efficacy are not well established. On the risk side, you have contamination/sterility issues, uncertain endocrine safety, and anti-doping problems. If someone wants predictable body-comp results, the smarter play is diet compliance, training, sleep, and proven medical options—not a gray-market peptide with thin human data.

Chatbot FAQ

Q: Does AOD-9604 actually burn fat? A: Maybe in preclinical models, but human proof is weak. The best data I found are animal studies and old phase IIa development notes, not strong clinical obesity outcomes.

Q: Is AOD-9604 the same as growth hormone? A: No. It is a fragment derived from the C-terminal region of human GH, designed to mimic some lipolytic effects without being full GH. That does not make it equivalent in safety, efficacy, or predictability.

Q: What is the half-life? A: Not well established in humans. I would not give a precise half-life as if it were a known clinical property.

Q: Is it banned in sport? A: Yes, it is treated as a banned performance-enhancing peptide in anti-doping literature, and athletes should assume it is prohibited. If testing matters, stay away.

Q: What dose should be used? A: There is no trustworthy evidence-based human dose from the sources reviewed here. Community doses exist online, but they are anecdotal and should not be treated as medical guidance.

Q: Is it injectable or oral? A: It is used as an injectable peptide in non-medical settings; oral bioavailability is not established and should not be assumed to work.

Sources

• AOD-9604 Metabolic - PubMed — Confirms development status for obesity and that phase IIa trials were underway; no public dose, half-life, or safety details in the accessible abstract.
• The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice - PubMed — Preclinical mechanism: reduced body weight and fat in obese mice after 14 days; involvement of beta-adrenergic/beta-3-AR expression; direct mediation through beta-3-AR not supported.
• Detection and in vitro metabolism of AOD9604 - PubMed — Defines AOD9604 as hGH 177-191 plus N-terminal tyrosine; reports urine detection method, LOD 50 pg/mL, six metabolites, stable metabolite CRSVEGSCG, and WADA ban language.
• AOD-9604 search results - PubMed — Shows relevant AOD-9604 records on PubMed including the metabolic review, WADA assay paper, and in vitro metabolism paper.
• The Prohibited List - WADA — Current WADA prohibited-list page reviewed; accessible page text did not explicitly name AOD-9604, so explicit naming could not be confirmed from the fetched content.

---

Data quality: Thin / experimental. Human clinical detail is sparse, and accessible sources do not establish a robust dose, half-life, onset, or safety profile. There is also a source mismatch on explicit WADA naming: PubMed identifies it as banned by WADA, while the accessible WADA page text reviewed here did not explicitly name it.